Your browser doesn't support javascript.
loading
Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).
Genta, Sofia; Lajkosz, Katherine; Yee, Noelle R; Spiliopoulou, Pavlina; Heirali, Alya; Hansen, Aaron R; Siu, Lillian L; Saibil, Sam; Stayner, Lee-Anne; Yanekina, Maryia; Sauder, Maxwell B; Keshavarzi, Sareh; Salawu, Abdulazeez; Vornicova, Olga; Butler, Marcus O; Bedard, Philippe L; Razak, Albiruni R Abdul; Rottapel, Robert; Chruscinski, Andrzej; Coburn, Bryan; Spreafico, Anna.
Afiliação
  • Genta S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Lajkosz K; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Yee NR; Toronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
  • Spiliopoulou P; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Heirali A; Toronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
  • Hansen AR; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Saibil S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Stayner LA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Yanekina M; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Sauder MB; Division of Dematology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
  • Keshavarzi S; Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
  • Salawu A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Vornicova O; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Butler MO; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Bedard PL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Razak ARA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
  • Rottapel R; Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Chruscinski A; University Health Network, University of Toronto, Toronto, ON, Canada.
  • Coburn B; Toronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
  • Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. anna.spreafico@uhn.ca.
J Exp Clin Cancer Res ; 42(1): 276, 2023 Oct 21.
Article em En | MEDLINE | ID: mdl-37865776

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autoantígenos / Inibidores de Checkpoint Imunológico Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Autoantígenos / Inibidores de Checkpoint Imunológico Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article